Dashboard
Manage Tickers

CDXCChromaDex Corp.

Nasdaq chromadex.com


$ 2.72 $ -0.04 (-1.45 %)    

Thursday, 20-Jun-2024 15:59:10 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 481.70 $ -3.74 (-0.77 %)
DIA $ 392.06 $ 2.93 (0.75 %)
SPY $ 546.68 $ -1.49 (-0.27 %)
TLT $ 93.95 $ -0.63 (-0.67 %)
GLD $ 218.15 $ 2.69 (1.25 %)
$ 2.71
$ 2.81
$ 0.00 x 0
$ 2.72 x 264
$ 2.72 - $ 2.89
$ 1.25 - $ 4.65
236,821
na
203.87M
$ 0.80
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 03-06-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-08-2023 12-31-2022 10-K
7 11-02-2022 09-30-2022 10-Q
8 08-10-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-14-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 08-03-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 03-12-2021 12-31-2020 10-K
15 11-04-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-18-2020 03-31-2020 10-Q
18 03-10-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 03-07-2019 12-31-2018 10-K
23 11-07-2018 09-30-2018 10-Q
24 08-09-2018 06-30-2018 10-Q
25 05-10-2018 03-31-2018 10-Q
26 03-15-2018 12-30-2017 10-K
27 11-09-2017 09-30-2017 10-Q
28 08-10-2017 07-01-2017 10-Q
29 05-11-2017 04-01-2017 10-Q
30 03-16-2017 12-31-2016 10-K
31 11-10-2016 10-01-2016 10-Q
32 08-11-2016 07-02-2016 10-Q
33 05-12-2016 04-02-2016 10-Q
34 03-17-2016 01-02-2016 10-K
35 11-12-2015 10-03-2015 10-Q
36 08-13-2015 07-04-2015 10-Q
37 05-14-2015 04-04-2015 10-Q
38 03-19-2015 01-03-2015 10-K
39 11-06-2014 09-27-2014 10-Q
40 08-12-2014 06-28-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

chromadex-unveils-niagen-with-fda-authorization-nrc-to-be-available-in-iv-shot-and-push-forms-at-clinics-nationwide
ChromaDex Unveils Niagen+ With FDA Authori...
06/13/2024 12:34:22

roth-mkm-maintains-buy-on-chromadex-maintains-6-price-target
Roth MKM Maintains Buy on ChromaDex, Maint...
06/12/2024 15:46:32

Roth MKM analyst Sean McGowan maintains ChromaDex (NASDAQ:CDXC) with a Buy and maintains $6 price target.

why-gamestop-shares-are-trading-lower-by-over-22-here-are-other-stocks-moving-in-fridays-mid-day-session
Why GameStop Shares Are Trading Lower By O...
06/07/2024 17:07:30

chromadex-announces-fda-orphan-drug-and-rare-pediatric-disease-designations-for-nrc-in-treatment-of-ataxia-telangiectasia-at
ChromaDex Announces FDA Orphan Drug And Ra...
06/07/2024 12:34:58

chromadex-gets-orphan-designation-status-from-fda-for-nicotinamide-riboside-chloride-for-treatment-of-ataxia-telangiectasia
ChromaDex Gets Orphan Designation Status F...
06/03/2024 15:51:16

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1004624

hc-wainwright--co-reiterates-buy-on-chromadex-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Chro...
05/09/2024 11:25:07

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ChromaDex (NASDAQ:CDXC) with a Buy and maintains $6 price target.

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
05/08/2024 20:31:13

chromadex-q1-2024-adj-eps-001-beats-002-estimate-sales-22200m-miss-23970m-estimate
ChromaDex Q1 2024 Adj EPS $(0.01) Beats $(...
05/08/2024 20:05:35

ChromaDex (NASDAQ:CDXC) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by ...

chromadex-announces-ingredient-partnership-with-solgar-solgar-cellular-nutrition-cellular-energy-features-niagen-to-support-nad-levels-for-cellular-health
ChromaDex Announces Ingredient Partnership...
04/30/2024 12:35:04

chromadex-launches-tru-niagen-at-the-vitamin-shoppe
ChromaDex Launches Tru Niagen At The Vitam...
04/25/2024 12:41:59

Tru Niagen is now available at 700 retail locations of The Vitamin Shoppe and Super Supplements™ and online at vitaminshoppe.com

chromadex-announces-that-its-flagship-product-tru-niagen-is-now-available-at-sprouts-farmers-market-marking-its-inaugural-major-grocery-debut
ChromaDex Announces That Its Flagship Prod...
04/23/2024 12:36:02

roth-mkm-maintains-buy-on-chromadex-raises-price-target-to-6
Roth MKM Maintains Buy on ChromaDex, Raise...
04/09/2024 13:59:19

Roth MKM analyst Sean McGowan maintains ChromaDex (NASDAQ:CDXC) with a Buy and raises the price target from $4.25 to $6.

12-health-care-stocks-moving-in-mondays-intraday-session
12 Health Care Stocks Moving In Monday's I...
03/18/2024 17:31:33

hc-wainwright--co-maintains-buy-on-chromadex-raises-price-target-to-6
HC Wainwright & Co. Maintains Buy on Chrom...
03/11/2024 11:23:13

HC Wainwright & Co. analyst Raghuram Selvaraju maintains ChromaDex (NASDAQ:CDXC) with a Buy and raises the price target ...

chromadex-expects-trajectory-of-2024-revenue-growth-to-continue-projecting-higher-rate-of-revenue-growth-than-prior-year-growth-of-16
ChromaDex Expects Trajectory Of 2024 Reven...
03/06/2024 21:23:13

chromadex-q4-eps-000-beats-003-estimate-sales-2120m-beat-2098m-estimate
ChromaDex Q4 EPS $0.00 Beats $(0.03) Estim...
03/06/2024 21:05:14

ChromaDex (NASDAQ:CDXC) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.03) by ...

earnings-scheduled-for-march-6-2024
Earnings Scheduled For March 6, 2024
03/06/2024 10:00:02

Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue o...

earnings-preview-for-chromadex
Earnings Preview For ChromaDex
03/05/2024 16:02:12

neurohacker-collective-and-chromadex-partner-to-optimize-cellular-health-with-the-debut-of-qualia-nad
Neurohacker Collective And ChromaDex Partn...
12/12/2023 15:31:51

Qualia NAD+, Featuring ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen, Well Positioned To Become Catego...

a-milestone-phase-i-randomized-double-blind-clinical-trial-demonstrates-high-dose-niagen-patented-nicotinamide-riboside-supplementation-induces-a-potent-nad-response-and-is-associated-with-mild-improvement-in-parkinsons-disease
A Milestone Phase I Randomized, Double-Bli...
11/30/2023 13:36:08

Building on a growing body of research showcasing NR as a potential therapeutic strategy for PD, this is the first clinical stu...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)